GLORIA PHARMA: Puxing Puli plans to transfer 20.64% equity of GLORIA PHARMA to repay the debts owed by Puxing Puli to the company
GLORIA PHARMA announced that it will resolve the debt dispute regarding the equity transfer payment with Pusheng Puli through an agreement. Pusheng Puli intends to transfer its 20.64% equity stake in GLORIA PHARMA to Youpeng Bio, and the proceeds will be used to repay debts owed to the company. The lawsuit regarding this equity transfer has entered the enforcement stage, and the subsequent process is complex and uncertain
According to the Zhitong Finance APP, GLORIA PHARMA (002437.SZ) announced that the company plans to resolve the debt dispute regarding the equity transfer payment of Guangzhou GLORIA Biotechnology Co., Ltd. (hereinafter referred to as "GLORIA Biotechnology") with Qingdao Pusheng Puli Enterprise Management Center (Limited Partnership) (hereinafter referred to as "Pusheng Puli") by signing the "Agreement of Guangzhou GLORIA Biotechnology Co., Ltd." The specific background, content, impact on the company, and risks are detailed.
The lawsuit between the company and Pusheng Puli regarding the equity transfer payment of GLORIA Biotechnology has entered the enforcement stage. The subsequent process will involve multiple steps including the assessment of GLORIA Biotechnology's equity, judicial auction, transfer of ownership, and payment of funds. The disposal process is complicated and lengthy, and the current assessment and pricing of GLORIA Biotechnology's equity face significant difficulties. Selling GLORIA Biotechnology's equity through conventional judicial procedures and recovering the equity transfer payment carries considerable uncertainty.
Pusheng Puli intends to transfer its 20.64% equity in GLORIA Biotechnology to Youpeng Biotechnology (Hainan) Co., Ltd. (hereinafter referred to as "Youpeng Biotechnology") and use the related funds to repay Pusheng Puli's debts to the company
